Abstract
With the emergence of information describing functional selectivity and biased agonists and antagonists has come a lack of confidence in “one size fits all” assays for detection of agonism. Seven-transmembrane receptors are pleiotropic with respect to the signaling protein to which they couple in a cell, and many conformations of the receptor can be formed; this leads to systems where ligands can stabilize unique conformations that go on to selectively activate signaling pathways. Thus, such “biased” ligands can produce cell-specific agonism that may require targeted assays to detect and quantify. It also predicts that ligands can have many different efficacies for the many behaviors that the receptor can exhibit (referred to as “pluridimensional efficacy”), leading to a breakdown in the common classifications of agonist and antagonist. This all poses unique challenges to the pharmacologic nomenclature of drugs, the detection and optimization of new drugs, and the association of phenotypic clinical profiles with pharmacological properties of drugs.
Footnotes
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.110.173948.
-
ABBREVIATIONS:
- GRK
- G protein-coupled receptor kinase
- ERK
- extracellular receptor kinase
- PTH
- parathyroid hormone
- TRV120027
- Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH.
- Received September 20, 2010.
- Accepted October 27, 2010.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|